IL-17A在卵巢癌组织中的表达及临床意义

The clinical significance of IL-17A expression and distribution in ovarian cancer

目的探讨炎症因子IL-17A在卵巢癌组织中的表达及其与卵巢癌患者临床病理特征间的关系。方法免疫组织化学法(immunohistochemistry,IHC)检测上皮性卵巢癌(34例)、卵巢交界性肿瘤(23例)、卵巢良性肿瘤(24例)石蜡组织切片中IL-17A的分布及表达情况,分析IL-17A表达与卵巢癌患者年龄、肿瘤大小、病理分型、临床分期、淋巴结转移等临床病理特征间的关系。结果免疫组化染色发现IL-17A主要表达在淋巴细胞胞浆,肿瘤细胞几乎不表达。卵巢癌患者组织中IL-17A阳性率为64.7%,卵巢交界性肿瘤和卵巢良性肿瘤患者组织中IL-17A阳性率分别为21.7%、8.3%。卵巢癌患者组织中IL-17A阳性表达水平明显高于卵巢交界性肿瘤、卵巢良性肿瘤患者,差异具有统计学意义(P<0.001;P<0.000 1)。IL-17A表达与卵巢癌患者病理分化水平、淋巴结转移相关(P<0.05),而与年龄、肿瘤大小、病理类型、临床分期无关。结论卵巢癌患者组织中高表达IL-17A可能参与卵巢癌患者疾病的进程,有望作为卵巢癌临床预后辅助预测指标。

This research was performed to investigate the expression of IL-17 A in ovarian cancer（OC） tissues,as well as its association with clinicopathological features. Immunohistochemistry method was applied to detect thedistribution and expression of IL-17 A infiltrated in ovarian cancer tissues（n=34）, borderline ovarian tumor tissues（n=23） and benign ovarian tumor tissues（n=24）. The relationship between IL-17 A expression andclinicopathological characteristics including age, tumor sizes, pathological type, clinical stages, differentiationgrades, and lymph node metastasis were analyzed in ovarian cancer patients. Analysis of Immunohistochemistryshowed that IL-17 A mainly located in lymphocytes, while almost none found in tumor cells. Further, the expressionrate of IL-17 A in ovarian cancer tissues（64.7%, 22/34） was significantly higher than that in borderline ovariantumor tissues（21.7%, 5/23） and benign ovarian tumor tissues（8.3%, 2/24）（P0.001; P0.000 1）. Moreover, theexpression of IL-17 A was positively correlated with differentiation degree and lymph node status in ovarian cancerpatients（P〈0.05）, while not with age, tumor size, pathological type, clinical stages. In conclusion, the excessiveexpression of IL-17 A in ovarian cancer tissues may participate in progression of ovarian cancer patients, whichcould be a poor prognosis marker for ovarian cancer.